Table 2.

Approaches for immunotherapy during acute and chronic FV infection.

Therapeutic	Improved immune response	Reference
Treg depletion	CD4+ T cells, CD8+ T cells, NK cells, B cells	(Zelinskyy et al. 2009a)
		(Dietze et al. 2011)
		(Manzke et al. 2013)
		(Littwitz-Salomon et al. 2015)
		(Littwitz-Salomon et al. 2018a)
		(Moore et al. 2018)
MDSC depletion	CD8+ T cells	(Drabczyk-Pluta et al. 2017)
PD-1/PDL-1 blockade	CD8+ T cells	(Dietze et al. 2013)
		(Akhmetzyanova et al. 2015)
Tim-3 blockade	CD8+ T cells	(Dietze et al. 2013)
Interferon-alpha subtypes	CD8+ T cells, NK cells	(Gerlach et al. 2009)
		(Gibbert et al. 2012)
TLR ligands	CD8+ T cells, B cells	(Olbrich et al. 2002)
		(Gibbert et al. 2010)
		(Kraft et al. 2005)
GITR agonist and blockade	CD8+ T cells, Tregs	(Dittmer et al. 2004)
		(He et al. 2004)
CD137 agonist	CD8+ T cells, CD4+ T cells	(Robertson et al. 2008b)
		(Malyshkina et al. 2017)
		(Malyshkina et al. 2019)
IL-15/IL-18 cytokines	NK cells	(Littwitz-Salomon, Schimmer and Dittmer 2017a)
IL-10 blockade	NK cells	(Littwitz-Salomon et al. 2018a)
CD122-directed IL-2	NK cells	(Littwitz-Salomon et al. 2015)
CD1d activator αGalCer	NK T cells	(Littwitz-Salomon, Schimmer and Dittmer 2017b)
IFNγ blockade	Antibodies, CD8+ T cells	(Stromnes et al. 2002)
		(Duley et al. 2012)